Takeaway

• The investigational drug molnupiravir taken twice daily for 5 days could significantly reduce infectious SARS-CoV-2 detectable in the nasopharynx.

Why this matters

• There is an urgent need for an antiviral drug against SARS-CoV-2 that is easy to produce, transport, store, and administer.
• Molnupiravir could potentially be the first oral...